Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives.
Lococo F, Ghaly G, Flamini S, Campanella A, Chiappetta M, Bria E, Vita E, Tortora G, Evangelista J, Sassorossi C, Congedo MT, Valentini V, Sala E, Cesario A, Margaritora S, Boldrini L, Mohammed A. Lococo F, et al. Among authors: bria e. J Thorac Dis. 2024 Oct 31;16(10):7096-7110. doi: 10.21037/jtd-24-244. Epub 2024 Oct 30. J Thorac Dis. 2024. PMID: 39552872 Free PMC article. Review.
Emerging pathways and future targets for the molecular therapy of pancreatic cancer.
Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M. Vaccaro V, et al. Among authors: bria e. Expert Opin Ther Targets. 2011 Oct;15(10):1183-96. doi: 10.1517/14728222.2011.607438. Epub 2011 Aug 7. Expert Opin Ther Targets. 2011. PMID: 21819318 Review.
Sorafenib for lung cancer: is the "Battle" still open?
Bria E, Pilotto S, Tortora G. Bria E, et al. Expert Opin Investig Drugs. 2012 Oct;21(10):1445-8. doi: 10.1517/13543784.2012.707191. Epub 2012 Jul 16. Expert Opin Investig Drugs. 2012. PMID: 22799503
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Pilotto S, Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G. Pilotto S, et al. Among authors: bria e. J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37. J Thorac Oncol. 2013. PMID: 24389444 Free article. No abstract available.
411 results